Skip to Content
Merck
CN
  • Reduced filaggrin expression is accompanied by increased Staphylococcus aureus colonization of epidermal skin models.

Reduced filaggrin expression is accompanied by increased Staphylococcus aureus colonization of epidermal skin models.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2014-10-30)
V van Drongelen, E M Haisma, J J Out-Luiting, P H Nibbering, A El Ghalbzouri
ABSTRACT

Atopic dermatitis is an inflammatory skin disease that is characterized by a reduced skin barrier function, reduced filaggrin (FLG) expression as well as increased colonization by Staphylococcus aureus. This study focused on the possible involvement of FLG in epidermal colonization by S. aureus and/or whether it affects the epidermal defence mechanisms, including the expression of antimicrobial peptides (AMPs) and enzymes involved in stratum corneum barrier lipid synthesis. Furthermore, IL-31 has been shown to reduce FLG expression, but its effects on bacterial colonization and on the expression of AMPs and enzymes involved in the barrier lipid synthesis are not known. We established N/TERT-based epidermal models (NEMs), after FLG knockdown (FLG-KD) and/or cultured with IL-31, that were colonized with S. aureus for 24 h. Both FLG-KD and IL-31 supplementation resulted in significantly increased epidermal S. aureus colonization, as well as in an up-regulation of S. aureus-induced IL-8 expression. IL-31, but not FLG-KD, prevented S. aureus-induced up-regulation of mRNA expression for the AMPs human β-defensin 2 and -3 and RNAse7, whereas psoriasin expression remained unchanged. Furthermore, the S. aureus colonization induced changes in mRNA expression of ELOVL4 was not affected by FLG-KD, but was blocked by IL-31. Expression of SCD-1 and Gcase mRNA was reduced by IL-31, but not by FLG-KD. This study shows that NEMs, with FLG-KD and/or cultured in the presence of IL-31, mimic the skin of patients with atopic dermatitis in several aspects, including enhanced bacterial colonization, increased inflammatory and reduced protective responses.

MATERIALS
Product Number
Brand
Product Description

Supelco
Glycerin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Palmitic acid, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Palmitic acid, United States Pharmacopeia (USP) Reference Standard
Palmitic acid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Glycerol solution, 83.5-89.5% (T)
Sigma-Aldrich
Palmitic acid, BioXtra, ≥99%
Sigma-Aldrich
Linoleic acid, technical, 58-74% (GC)
Sigma-Aldrich
Palmitic acid, ≥98%, FCC, FG
Sigma-Aldrich
Palmitic acid, ≥99%
Sigma-Aldrich
Linoleic acid, liquid, BioReagent, suitable for cell culture
Sigma-Aldrich
Palmitic acid, ≥98% palmitic acid basis (GC)
Supelco
Palmitic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Glycerol solution, puriss., meets analytical specification of Ph. Eur., BP, 84-88%
Serine, European Pharmacopoeia (EP) Reference Standard
Supelco
Calcium standard for AAS, analytical standard, 1.000 g/L Ca2+ in hydrochloric acid, traceable to BAM
Supelco
Linoleic acid, analytical standard
Supelco
Palmitic acid, analytical standard
Sigma-Aldrich
Palmitic acid, natural, 98%, FG
USP
Glycerin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Calcium chloride, AnhydroBeads, −10 mesh, ≥99.99% trace metals basis
Sigma-Aldrich
Arachidonic acid, from non-animal source, ≥98.5% (GC)
Sigma-Aldrich
Calcium chloride, powder, 99.99% trace metals basis
Sigma-Aldrich
Glycerol, FCC, FG
Sigma-Aldrich
Calcium chloride, AnhydroBeads, −10 mesh, ≥99.9% trace metals basis
Sigma-Aldrich
Selenous acid, 99.999% trace metals basis
Sigma-Aldrich
Arachidonic acid, >95.0% (GC)
Sigma-Aldrich
Calcium chloride, anhydrous, BioReagent, suitable for insect cell culture, suitable for plant cell culture, ≥96.0%
Sigma-Aldrich
Calcium chloride
Sigma-Aldrich
DL-Serine, ≥98% (TLC)
Sigma-Aldrich
Glycerol, ≥99.5%